Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
35 hedge funds and large institutions have $385K invested in Statera Biopharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
57% less capital invested
Capital invested by funds: $897K → $385K (-$512K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$21.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$18.8K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$18.4K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.15K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$58.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$28.6K |
| 3 |
Jane Street
New York
|
-$10K |
| 4 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$5K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
26
Archer Investment Corporation
Carmel,
Indiana
| $39 | – | – | – |
|
|
27
Jane Street
New York
| – | -$10K | -35,422 | Closed |
|
|
BPA
28
Beacon Pointe Advisors
Newport Beach,
California
| – | -$5K | -18,494 | Closed |
|
29
Simplex Trading
Chicago,
Illinois
| – | -$31 | -148 | -74% |
|
30
Morgan Stanley
New York
| – | -$1 | -3 | -75% |
|
31
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$2 | +9 | New |
|
32
Wells Fargo
San Francisco,
California
| – | +$103 | +491 | +181% |
|
STAB Hedge Fund Activity: Q3 2022 in Review
35 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2022, worth a combined $385K — down 57% from $897K a quarter earlier.
Fund positioning in STAB was balanced in Q3 2022: 2 funds opened new positions, 2 closed out, 6 added to existing stakes and 8 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $21.6K. The largest seller was Renaissance Technologies, cutting an estimated $58.8K.
- 35 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $385K of Statera Biopharma, Inc. Common Stock stock for Q3 2022, down 57% quarter-over-quarter.
- 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2022 and 2 closed out, a net change of 0 holders.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2022 was Virtu Financial, an estimated $21.6K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $58.8K sold.
Based on aggregated 13F filings for Q3 2022.